Hyaluronidase in ophthalmology

Journal of Applied Research

Volumn 12, Issue 1, 2012, Pages 1-13

  Silverstein, Steven M ^a,b   Greenbaum, Scott ^c,d   Stern, Robert ^e,f  

^a Silverstein Eye Centers   (United States)

^b KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

^c Greenbaum Eye Associates   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Touro/Harlem College of Osteopathic Medicine ^*  (United States)

^f Touro College and University System   (United States)

Author keywords

Compounding; Hyaluronidase; Peribulbar block; Recombinant human hyaluronidase; Retrobulbar block; Sub tenon's block

Indexed keywords

CONTRAST MEDIUM; HYALURONIDASE; LOCAL ANESTHETIC AGENT; RECOMBINANT HYALURONIDASE; RHUPH 20; UNCLASSIFIED DRUG;

AKINESIA; ANAPHYLAXIS; ANESTHESIA; ANGIONEUROTIC EDEMA; ARTICLE; CHEMOSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG CONTAMINATION; DRUG HYPERSENSITIVITY; DRUG IMPURITY; DRUG MECHANISM; DRUG POTENCY; DRUG PURITY; DRUG QUALITY; DRUG RECALL; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ECCHYMOSIS; ERYTHEMA; EXOPHTHALMOS; EYE MOVEMENT DISORDER; EYE SURGERY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HUMAN; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; INTRAOCULAR PRESSURE; LABORATORY TEST; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MUSCLE DISEASE; OPHTHALMOLOGY; PAIN; PERIBULBAR ANESTHESIA; PERIORBITAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); POLYACRYLAMIDE GEL ELECTROPHORESIS; PRURITUS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHYDRATION; RETROBULBAR ANESTHESIA; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN REDNESS; SUNTENON ANESTHESIA; UNSPECIFIED SIDE EFFECT; URTICARIA; VITREOUS HEMORRHAGE; WESTERN BLOTTING;

EID: 84861744080     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Atkinson WS. Use of hyaluronidase with local anesthesia in ophthalmology: preliminary report. Arch Opthalmol. 1949; 42:628-633.
2. Leibovitch I, Tamblyn D, Casson R, Selva D. Allergic reaction to hyaluronidase: a rare cause of orbital inflammation after cataract surgery. Graefe's Arch Clin Exp Ophthalmol. 2006; 244:944-949.
3. Center for Drug Evaluation and Research. Hyaluronidase Adverse Event Data (AERS); August 5, 2011.
4. Chalk E, Duthie ES. A mucolytic enzyme in testis extracts [letter]. Nature. 1939; 144:977-978.
5. Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Rel. 2006; 114:230-241.
6. Day TD. The permeability of interstitial connective tissue and the nature of the interfibrillary substance. J Physiol. 1952; 117:1-8.
7. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions, and turnover. J Intern Med. 1997; 242:27-33.
8. Hylenex recombinant (hyaluronidase human injection) [package insert]. San Diego, CA: Halozyme Therapeutics; August 2011.
9. Spandorfer PR. Subcutaneous rehydration: updating a traditional technique. Pediatr Emerg Care. 2011; 27:230-236.
10. United States Department of Veterans Affairs. Hyaluronidase monograph (Amphadase, Hydase, Vitrase, Hylenex) final. http://www.pbm.va.gov/DrugMonograph.aspx. Accessed August 31, 2011.
11. Dempsey GA, Barrett PJ, Kirby IJ. Hyaluronidase and peribulbar block. Br JAnaesth. 1997; 78:671-674.
12. Canavan KS, Dark A, Garrioch MA. Sub-Tenon's administration of local anaesthetic: a review of the technique. Br JAnaesth. 2003; 90:787-793.
13. Prosser DP, Rodney GE, Mian T, Jones HM, Khan MY. Re-evaluation of hyaluronidase in peribulbar anaesthesia. Br J Ophthalmol. 1996; 80:827-830.
14. Brown SM, Coats DK, Collins ML, Underdahl JP. Second cluster of strabismus cases after periocular anesthesia without hyaluronidase. J Cataract Refract Surg. 2001; 27:1872-1875.
15. Hamada S, Devys JM, Xuan TH, et al. Role of hyaluronidase in diplopia after peribulbar anesthesia for cataract surgery. Ophthalmology. 2005; 112:879-882.
16. Remy M, Pinter F, Nentwich MM, Kampik A, Schöfeld CL. Efficacy and safety of hyaluronidase 75 IU as an adjuvant to mepivacaine for retrobulbar anesthesia in cataract surgery. JCataract Refract Suurg. 2008; 34:1966-1969.
17. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR, For the Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase®) for the manage-ment of vitreous hemorrhage. Am J Ophthalmol. 2005; 140:585-597.
18. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR, For the Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase®) for the manage-ment of vitreous hemorrhage. Am J Ophthalmol. 2005; 140:573-584.
19. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Dermatology and Ophthalmic Drugs Advisory Committee. 2003. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3929T1.pdf. Accessed October 11, 2011.
20. Leaming DV. Practice styles and preferences of ASCRS members2003 survey. J Cataract Refract Surg. 2004; 30:892-900.
21. Nouvellon E, Cuvillon P, Ripart J, Viel EJ. Anaesthesia for cataract surgery. Drugs Aging. 2010; 27:21-38.
22. Kallio H, Paloheimo M, Maunuksela EL. Hyaluronidase as an adjuvant in bupivacaine-lidocaine mixture for retrobulbar/peribulbar block. Anesth Analg. 2000; 91: 934-937.
23. De Broff BM, Hamilton RC, Loken RG, Gimbel HV, Ferensowicz M. Retrobulbar anesthesia with 7.5 vs. 0.75 IU/mL of hyaluronidase. Can J Ophthalmmol. 1995; 30:262-264.
24. Johansen J, Kjeldgård M, Corydon L. Retrobulbar anaesthesia: a clinical evaluation of four different anaesthetic mixtures. Acta Ophthalmol. 1993; 71:787-790.
25. Krohn J, Seland JH, Hovding G, Bertelsen T, Aasved H, Haugen OH. Retrobulbar anesthesia with and without hyaluronidase in extracapsular cataract surgery: a prospective, randomized, double-blind study. Acta Ophthahnol. 1993; 71:791-795.
26. Abelson MB, Mandel E, Paradis A, George M. The effect of hyaluronidase on akinesia during cataract surgery. Ophthalmic Surg. 1989; 20:325-326.
27. Thomson I. Addition of hyaluronidase to lignocaine with adrenaline for retrobulbar anaesthesia in the surgery of senile cataract. Br J Ophthalmol. 1988; 72:700-702.
28. Nicoll JMV, Treuren B, Acharya A, Ahlen K, James M. Retrobulbar anesthesia: the role of hyaluronidase. Anesth Analg. 1986; 65:1324-1328.
29. Mindel JS. Value of hyaluronidase in ocular surgical akinesia. Am JOphthalmol. 1978; 85:643-646.
30. Jankovic D, ed. Regional Nerve Blocks and Infiltration Therapy. Textbook and Color Atlas. 3rd ed. http://www.scribd.com/doc/39463186/Regional-Nerve-Blocks-and-Infiltration-TherapyTextbook-and-Color-Atlas-3rd-Ed?query-van+lint. Accessed August 31, 2011.
31. Greenbaum S. Anesthesia for eye surgery. In: Tasman W, Jaeger EA, eds. Duane's Ophthalmology. On CD-ROM. 2006 ed. http://www.oculist.net/downaton502/prof/ebook/duanes/index.html. Accessed October 17, 2011.
32. Pacella E, Collini S, Pacella F, Piraino DC, Santamaria V, DeBlasi RA. Levobupivacaine vs. racemic bupivacaine in peribulbar anaesthesia: a randomized double blind study in ophthalmic surgery. Eur Rev Med Pharmacol Sci. 2010; 14:539-544.
33. Mantovani C, Bryant AE, Nicholson G. Efficacy of varying concentrations of hyaluronidase in peribulbar anaesthesia. Br JAnaesth. 2001; 86:876-878.
34. van den Berg AA, Montoya-Pelaez LF. Comparison of lignocaine 2% with adrenaline, bupivacaine 0.5% with or without hyaluronidase and a mixture of bupivacaine, lignocaine and hyaluronidase for peribulbar block analgesia. Acta Anaesthesiol Scand. 2001; 45:961-966.
35. Brydon CW, Basler M, Kerr WJ. An evaluation of two concentrations of hyaluronidase for supplementation of peribulbar anaesthesia. Anaesthesia. 1995; 50:998-1000.
36. Crawford M, Kerr WJ. The effect of hyaluronidase on peribulbar block. Anaesthesia. 1994; 49:907-908.
37. Mather C, Smith JH, Bloom PA. The efficacy of 0.75% bupivacaine with pH adjustment and hyaluronidase for peribulbar blockade: the incidence of prolonged ptosis. Eur J Ophthalmol. 1994; 4:13-18.
38. Roberts JE, MacLeod BA, Hollands RH. Improved peribulbar anaesthesia with alkalinization and hyaluronidase. Can J Anaesth. 1993; 40:835-838.
39. Sarvela J, Nikki P. Hyaluronidase improves regional ophthalmic anaesthesia with etidocaine. Can JAnaesth. 1992; 39:920-924.
40. Greenbaum S. The first use of recombinant human hyaluronidase in cataract surgery anesthesia: a pilot study [poster 263]. Presented at the annual meeting of the American Academy of Ophthalmology; November 10-13, 2007; New Orleans, LA.
41. Schulenburg HE, Sri-Chandana C, Lyons G, Columb MO, McLure HA. Hyaluronidase reduces local anaesthesic volumes for sub-Tenon's anaesthesia. Br JAnaesth. 2007; 99:717-720.
42. Aslam S, Sarker SJ, Tran-Dang M, et al. Effect of hyaluronidase on ocular motility and eyelid function in sub-Tenon's anaesthesia: randomised controlled trial. Eye. 2006; 20:579-582.
43. Alwitry A, Chaudhary S, Gopee K, Butler TKH, Holden R. Effect of hyaluronidase on ocular motility in sub-Tenon's anesthesia: randomized controlled trial. J Cataract Refract Surg. 2002; 28:1420-1423.
44. Moharib MM, Mitra S, Rizvi SG. Effect of alkalinization and/or hyaluronidase adjuvancy on a local anesthetic mixture for sub-Tenon's ophthalmic block. Acta Anaesthesiol Scand. 2002; 46:599-602.
45. Rowley SA, Hale JE, Finlay RD. Sun-Tenon's local anaesthesia: the effect of hyaluronidase. BrJ Ophthalmol. 2000; 84:435-436.
46. Guise P, Laurent S. Sub-Tenon's block: the effect of hyaluronidase on speed of onset and block quality. Anaesth Intensive Care. 1999; 27:179-181.
47. Hydase (hyaluronidase injection) [package insert]. San Diego, CA: PrimaPharm, Inc.; 2005.
48. Amphadase (hyaluronidase injection USP) [package insert]. Rancho Cucamonga, CA: Amphastar Pharmaceuticals, Inc.; November 2005.
49. Vitrase (hyaluronidase injection) ovine, 200 USP units/mL [package insert]. Irvine, CA: ISTA Pharmaceuticals; 2010.
50. American Society of Health-System Pharmacists. Hyaluronidase Injection. June 17, 2011. http://www.ashp.org/DrugShortages/Current/bulletin.aspx?id=580. Accessed June 21, 2011.
51. Hagan JC III, Hill WE. Use of a compounding pharmacy hyaluronidase for ophthalmic injection anesthesia [letter]. J Cataract Refract Surg. 2001; 27:1712-1714.
52. BBI Enzymes. Hyaluronidase/Mucopolysaccharidase. http://www.bbienzymes.com/content_202_. Accessed June 21. 2011.
53. Benditt EP, Schiller S, Mathews MB, Dorfmman A. Evidence that hyaluronidase is not the factor in testicular extract causing increased vascular permeability. Proc Soc Exp Biol Med. 1951; 77:643-645.
54. Britton RC, Habif DV. Recent advances in surgery. Surgery. 1953; 33(6):917-942.
55. Kind LS, Roffler S. Adverse rections to hyaluronidase. Proc Soc Exp Biol Med. 1961; 106:734-735.
56. Schwartzman J. Hyaluronidase in pediatrics. NY State J Med 1951; 215-221.
57. Lee HK, Choi EJ, Lee PB, Nahm FS. Anaphylactic shock caued by the epidurally-administered hyalurinidase. Korean JPain. 2011 Dec; 24(4):221-225.
58. Jehan FS, Hagan JC III, Whittaker TJ, Subramanian M. Diplopia and ptosis following injection of local anesthesia without hyaluronidase. J Cataract Refract Surg. 2001; 27:1876-1879.
59. DIYSite.com. Hyaluronidase. http://www.diytrade.com/china/4/products/4561969/Hyaluronidase.html. Accessed August 31, 2011.
60. EMD Chemicals. http://www.emdchemicals.com/is-bin/INTERSHOP.enflnity/WFS/Merck-US-Site/en_CA. Accessed June 20, 2011.
61. Sigma-Aldrich. Hyaluronidase. http://www.sigmaaldrich.com/technical-service-home/product-catalog.html. Accessed August 31, 2011.
62. Allen LV Jr. Hyaluronidase 150 u/mL injection. U.S. Pharmacist. 2001; 26:68 71.
63. Formulations. Int J Pharm Comnp. 2001; 5:299-309
64. US Food and Drug Administration. Drugs. Application of federal law to practice of pharmacy compounding. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155666.htm. June 18, 2009. Accessed August 31, 2011.
65. Committee on Health, Education, Labor, and Pensions. Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients. October 23, 2003. http://ftp.resource.org/gpo.gov/hearings/I08s/90129.txt. Accessed August 8, 2011.
66. US Food and Drug Administration. Drugs. Report: limited FDA survey of compounded drug products. http://www.fda.gov/Drugs/GuidanceCompliance-RegulatoryInformation/PharmacyCompounding/ucm155725.htm. June 18, 2009. Accessed August 31, 2011.
67. Jumper JM, McCauley MB, Equi RA, Duncan KG, Duncan J, Schwartz DM. Corneal toxicity of intraocular hyaluronidase. J Ocul Pharmacol Ther. 2002; 18:89-97.
68. Delaere L, Zeyen T, Foets B, Van Calster J, Stalmans I. Allergic reaction to hyaluronidase after retrobulbar anaesthesia: a case series and review. Int Ophthalmol. 2009; 29:521-528.
69. Eberhart AH, Weiler CR, Erie JC. Angioedema related to the use of hyaluronidase in cataract surgery. Am J Ophthalmol. 2004; 138:142-143.
70. Kempeneers A, Dralands L, Ceuppens J. Hyaluronidase induced orbital pseudotumor as complication of retrobulbar anesthesia. Bull Soc Belge Ophtalmol. 1992; 243:159-166.
71. Kim TW, Lee JH, Yoon KB, Yoon DM. Allergic reactions to hyaluronidase in pain management- a report of three cases. Korean JAnesthesiol. 2011; 60:57-59.
72. Kirby B, Butt A, Morrison AM, Beck MH. Type I allergic reaction to hyaluronidase during ophthalmic surgery. Contact Dermatitis. 2001; 44:52.
73. Minning CA Jr. Hyaluronidase allergy simulating expulsive choroidal hemorrhage. Arch Ophthalmol.1994; 112:585-586.
74. Quhill F, Bowling B, Packard RB. Hyaluronidase allergy after peribulbar anesthesia with orbital inflammation. J Cataract Refract Surg. 2004; 30:916-917.
75. Taylor IS, Pollowitz JA. A little-known phenomenon: allergic reaction to hyaluronidase. Ophthalmology. 1984; 91:1003.
76. Varma D, Metcalfe TW. Orbital cellulitis after peribulbar anaesthesia for cataract surgery. Eye (Lond). 2003; 17:105-106.
77. Youssef Z, Pennefather PM, Watts MT. Orbital cellulitis vs allergic reaction to hyaluronidase as the cause of periorbital oedema. Eye (Lond). 2005; 19:691-692.
78. Ahluwalia HS, Lukaris A, Lane CM. Delayed allergic reaction to hyaluronidase: a rare sequel to cataract surgery [letter]. Eye. 2003; 17:263-266.
79. Escolano F, Pares N, Gonzalez I, Castillo J. Allergic reaction to hyaluronidase in cataract surgery [letter]. Eur J Anaesthesiol. 2005; 22:729-730.
80. Musa F, Srinivasan S, King CM, Kamal A. Raised intraocular pressure and orbital inflammation: a rare IgE-mediated allergic reaction to sub-Tenon's hyaluronidase [letter]. J Cataract Refract Surg. 2006; 32:177-178.
81. Nicholson G, Hall GM. Allergic reaction to hyaluronidase after a peribulbar injection [letter]. Anaesthesia. 2003; 58:814-815.
82. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. JInfus Nurs. 2007; 30:293-299.
83. Vartanian AJ, Frankel AS, Rubin MG. Injected hyaluronidase reduces Restalyne-mediated cutaneous augmentation. Arch Facial Plast Surg. 2005; 7:231-237.
84. Allen CH, Etzwiler LS, Miller MK, et al, For the Increased Flow Utilizing SubcutaneouslyEnabled Pediatric Rehydration Study Collaborative Research Group. Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration. Pediatrics. 2009; 124:e858-e867.
85. Spandorfer PR, Friend K, Harb G., Recombinant human hyaluronidase-facilitated subcutaneous vs intravenous rehydration therapy in children. Presented at the 2010 Pediatric Academic Societies'Annual Meeting; May 1-4, 2010; Vancouver, Canada.
86. Dychter S, Ebel D, Mead TR, Yocum RC. Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: a phase IV doubleblind, randomized pilot study in health volunteers. Curr Ther Res. 2009; 70:421-438.
87. Thomas JR, Yocum RC, Haller MF, von Gunten CF. Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. JPalliat Med. 2007; 10:1312-1320.
88. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010; 26:279-288.
89. Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. JPain Symptom Manage. 2009; 38:663-672.
90. Thomas JR, Yocum RC, Haller MF, Flament J. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers. J Pain Sympton Manage. 2009; 38:673-682.
91. Greenbaum S. The first use of recombinant human hyaluronidase in cataract surgery anesthesia: a pilot study [poster 263]. Presented at the annual meeting of the American Academy of Ophthalmology; November 10-13, 2007; New Orleans, LA.